Minimal residual disease (MRD) can today be evaluated in individual patient after treatment using various methods with high sensitivity. MRD indicates remaining malignant cells that could be a source of relapse of the disease. Could MRD also be used as an efficient endpoint in the design of new clinical studies? With help from Professor Ola Landgren, we will look into the crystal ball and discover what the future may hold for MRD.
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Ola Landgren, Professor of Medicine, Chief of Myeloma Program & Experimental Therapeutics Program. Sylvester Comprehensive Cancer Center, University of Miami
MAT-BE-2200984 (1.0) 12 2022
